Bayer has been stepping up its game behind its Bayer Advanced Aspirin brand in an attempt to recreate its brand identity from a healthy heart supplement for people who’ve had a heart attack to what Bayer Aspirin had been in its heyday: the internal analgesic of choice.
A large new observational study published Friday found more evidence of an association between daily aspirin use and modestly lower cancer mortality, but suggested any reduction may be smaller than that observed in a recent analysis. The study appeared online in the Journal of the National Cancer Institute.
To encourage consumers to rethink aspirin for pain relief — according to a recent Bayer survey, only 8% of respondents reported taking aspirin more often that other OTC pain relievers — Bayer on Tuesday issued the Fast Relief Challenge and is giving away 100,000 bottles of Bayer Advanced Aspirin so consumers can put the pain reliever to the test.
Annapolis, Md.-based St. Joseph Consumer Health last week unveiled a new St. Joseph-branded line of cough cold products formulated for patients with high blood pressure at the ECRM Cough & Cold and Allergy EPPS.
A recent clinical trial involving a new drug formulation incorporating aspirin with soy-derived phosphatidylcholine found that the drug combination significantly can reduce irritation to the stomach and upper gastrointestinal tract.